CETUXIMAB

Cetuximab is an EGFRblocking monoclonal antibody for colorectal and headneck cancers. Side effects include rash, infusion reactions, and hypomagnesemia. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 29934220133a Category: Tag:

Product Description


Mechanism of Action

Cetuximab is a chimeric monoclonal IgG1 antibody targeting the epidermal growth factor receptor (EGFR). It binds the extracellular domain of EGFR, preventing ligand binding and inhibiting receptor dimerisation, internalisation and autophosphorylation. This suppresses downstream RAS/RAF/MEK/ERK and PI3K/AKT signalling, inhibiting proliferation, angiogenesis and tumourcell survival.

Benefits and Advantages

Used in EGFRpathway research, oncology models, cellsignalling studies, KRASmutation resistance investigations, antibodyreceptor binding kinetics, and monoclonalantibody pharmacology.

Side Effects and Risks

Risks include infusion reactions, severe acneiform rash, electrolyte imbalance (esp. hypomagnesaemia), interstitial lung disease and immunogenicity. Handle using biologicagent containment.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C6500H10176N1720O2024S42

Molecular Weight

152000.0 g/mol

CAS Number

205923-56-4

Storage Condition

Store in a cool, dry place; protected from light

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

MLS002608064; CHEMBL1736329; HMS3092B19; AKOS024323068; isonicotinaldehyde O-(2-phenylethyl)oxime

IUPAC/Chemical Name

Chimeric monoclonal IgG1 antibody

InChl Key

Unavailable for large molecules

InChl Code

Unavailable for large molecules

References

PubChem; ChemBL; FDA substance registry;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download